Status:
COMPLETED
Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
This study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (EGCG), in multiple sclerosis patients.
Eligibility Criteria
Inclusion
- Patients with relapsing-remitting multiple sclerosis
- stable treatment with glatiramer acetate at least 6 months prior to inclusion
- Expanded disability status scale \< 4.5
- Normal weight, overweight
Exclusion
- Primary or secondary progressive forms of multiple sclerosis
- Clinically relevant heart, lung, liver, kidney diseases
- Habitual caffeine intake over 300 mg per day
- Habitual consumption of green tea
- Alcohol or drug abuse
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01417312
Start Date
July 1 2011
End Date
January 1 2013
Last Update
July 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Franz-Volhard Clinical Research Center at the Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine
Berlin, Germany, 13125